ASH 2024 – Jaypirca's confirmation, despite no survival
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
ASH 2024 – AstraZeneca aims to fix Calquence’s position
But with Brukinsa and degraders looming, will fixed dosing make the difference?
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
EHA 2024 – Nurix and BeiGene’s degraders shine
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
Ascentage’s Venclexta challenge looks wildly optimistic
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
